Healthcare / Medical Instruments & SuppliesTokyo
$492.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $1.7B · quality 40.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$52.4B
P/E
14.3x
↓EV/EBITDA
6.4x
↓ROE
36.3%
↑Gross Margin
68.6%
↑Debt/Equity
0.83
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.2%
FCF CAGR
-41.3%
FCF margin
9.1%
FCF / Net income
0.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $18.63B · net income $6.32B · FCF $1.70B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $18.63B | $18.63B | $18.43B | $15.67B | $17.46B |
| Net Income | $6.32B | $6.32B | $5.77B | $3.03B | $4.48B |
| EBITDA | $9.02B | $9.02B | $8.54B | $5.32B | $8.55B |
| EPS | 58.90 | 58.90 | 53.99 | 30.35 | 44.81 |
| Gross Margin | 68.6% | 68.6% | 67.8% | 58.7% | 84.1% |
| Operating Margin | 44.4% | 44.4% | 43.6% | 31.7% | 64.1% |
| Net Margin | 33.9% | 33.9% | 31.3% | 19.4% | 25.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.83 | 0.83 | 0.70 | 0.76 | 0.67 |
| Current Ratio | 1.44 | 1.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.70B | $1.70B | $5.97B | $-4.32B | $8.39B |
| Returns | |||||
| ROE | 36.3% | 36.3% | 42.2% | 35.7% | 60.9% |
| Valuation | |||||
| P/E | 14.33 | 14.33 | 7.59 | — | — |
| EV/EBITDA | 6.42 | 6.42 | 5.15 | — | — |
| P/B | 3.03 | 3.03 | 3.21 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 1.0% | 1.0% | 17.6% | -10.2% | — |
| EPS Growth | 9.1% | 9.1% | 77.9% | -32.3% | — |
| Dividend Yield | 5.7% | 5.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-9.5%
EPS terminal req.
$43.66
Spread vs growth
18.6%
5Y implied EPS CAGR
-2.2%
EPS terminal req.
$52.82
Spread vs growth
11.2%
10Y implied EPS CAGR
3.7%
EPS terminal req.
$85.07
Spread vs growth
5.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.4%
Start / end P/E
10.0x → 8.4x
EPS bridge
53.99 → 58.90
Residual
-1.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.